Etoposide

目录号:S1225 别名: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。

规格 价格 库存 购买数量  
RMB 749.41 现货
RMB 575.72 现货
RMB 2290.17 现货
RMB 5648.26 现货
RMB 8114.83 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。
靶点
Topo II [2]
(Cell-free assay)
体外研究

Etoposide通过与Topoisomerase II 和 DNA形成复合物而抑制DNA合成,诱导双链DNA断裂,且阻碍通过 Topoisomerase II结合修复。DNA持续断裂阻碍进入细胞有丝分裂期,进而导致细胞死亡。Etoposide主要作用于细胞周期的G2期和S期。[1] Etoposide 抑制鼠类血管肉瘤细胞系 (ISOS-1) 生长,IC50 为0.25 μg/mL。Etoposide 抑制人类白血病成淋巴细胞系CCRF-CEM的四倍体克隆,IC50为0.6 μM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrHcHd7UUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> MoTvNlU6PjB{OEK=
KellyCis83 NHq2XGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjKTWM2OD1yLkG25qCKyrIkgJmwMlAzKM7:TR?= M4jIVVI2QTZyMkiy
SK-N-AS Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fwRWlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= NFjublIzPTl4MEK4Ni=>
SK-N-ASCis24 M4Xl[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvoTWM2OD1yLkW35qCKyrIkgJmwMlEyKM7:TR?= MWmyOVk3ODJ6Mh?=
U87 NHrOR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK4eoYxNTVyIN88US=> NGriVZk1QCCq MVnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KHOrbHnibY5qdg>? NELXSWUzPTd3MEK3Ny=>
HCT116 NYDveYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLLNE42NTJwNTFOwG0> NUf2NW5UPDkEoHlCpC=> NILDd4JKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= M1PIW|I2PzR4N{[z
HT-29 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\1NE42NTJwNTFOwG0> M3rYXFQ5yqCqwrC= Mof0TWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? NIC1Om4zPTd2Nke2Ny=>
Caco2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37zOFAvPS1{LkWg{txO NUT2NoJLPDkEoHlCpC=> MoDSTWM2OD15LkK2xsDDucLiMT62POKh|ryP NWe5ZVhkOjV5NE[3OlM>
COLO 205 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;QXpRIOC53LUKuOUDPxE1? NE\hXGc1QMLiaNMg NITsR2RKSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= Mn7pNlU4PDZ5NkO=
SW480 MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fxfFAvPS1{LkWg{txO MVG0POKhcMLi MkjKTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP M13KelI2PzR4N{[z
HEK293T NIjvPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxMVUh|ryP MYK0POKhcMLi M1fhTWlEPTB;Mj60NuKhyrIEoECuNFXDqM7:TR?= NIDFNoMzPTd2Nke2Ny=>
Hep3B  Ml\ySpVv[3Srb36gRZN{[Xl? MkLENVAh|ryP MWe0POKhcMLi NVf4TWcyemWmdXPld{B1cGViZX7oZY5kcW6pIHXm[oVkfCCxZjDCUXAuPg>? NFLRXpAzPTZ|M{W2OC=>
Hep3B  MWfGeY5kfGmxbjDBd5NigQ>? MYCwMlEuOTBizszN NFv2[lkzPCCq MX;zeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? M2jIZlI2PjN|NU[0
HEK293 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;FZotKSzVyPUeuNVTDqMLzwrCwMlM3yqEQvF2= NHzhcoUzPTZyM{GyNi=>
DU145 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr5PFJKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= MmPJNlU3ODNzMkK=
HCT15 M3PxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHqeXBKSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= M1L4TVI2PjB|MUKy
T47D NV76No57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDRT4JXUUN3ME2zMlE5yqEEsdMgNE4yOcLizszN NEXmbpYzPTZyM{GyNi=>
SMMC-7721 NYW2fG8zTnWwY4Tpc44hSXO|YYm= NIXlZnM1OCEQvF2= NWLNdmdpPDhiaB?= M3fpS2ROW09? M1;T[4lv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v MmP3NlU2PDR|NkG=
MDA-MB-231 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[3NuKhcA>? NG\OcpFKSzVyPUKxMlLDqMLzwrC0MlLDqM7:TR?= M1zp[|I2PDh4MkG5
MCF-7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq3NuKhcA>? MlzVTWM2OD1zMD65xsDDucLiMj6xxsDPxE1? NFXnPWozPTR6NkKxPS=>
Jurkat Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ueVczyqCq MVjJR|UxRTFwMtMgxtHDqDFwNdMg{txO NIfOblMzPTR6NkKxPS=>
HeLa MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\6[nE4OsLiaB?= MWnJR|UxRTNwOdMgxtHDqDJwM9Mg{txO MlvYNlU1QDZ{MUm=
MCF7  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVe1MVExOCEQvF2= NEDtW3Y4KGR? NVXhcWpWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkfRNlU1PzJ4MUm=
K562 NYjrT2p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnvNVc4OsLiaB?= NWDaOnNkUUN3ME2wMlI6yqEQvF2= MXqyOVI5OjZ3Mx?=
K/VP.5 NYm4eVdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rFbVczyqCq NFPEdYdKSzVyPUSuPeKh|ryP NXfieGZXOjV{OEK2OVM>
SH-EP  NFnvV21HfW6ldHnvckBCe3OjeR?= NIrHNlYzOMLizsznM41t MY[yOOKhcA>? MW\pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[Y5ld2enbn;1d{BFTVCS MU[yOVI3OTl6MR?=
SCC25 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfzfoozPMLiaB?= MVLJR|UxRTR|LkRCpOKyyqBzLkGyxsDPxE1? Ml3iNlUzOjB5Mkm=
CAL27 NXvMbGc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDTbYgzPMLiaB?= MlXNTWM2OD13Mj6xxsDDucLiMT6wPeKh|ryP MX:yOVIzODd{OR?=
FaDu MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzNO3UzPMLiaB?= MVPJR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP M1Px[lI2OjJyN{K5
SCC25 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT1enk1QMLiaB?= MXPJR|UxRTJyLki2xsDDucLiMT6wO:Kh|ryP MVyyOVIzODd{OR?=
CAL27 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe0POKhcA>? M4jCWWlEPTB;MUiuNlTDqMLzwrCxMlE2yqEQvF2= NGi3bY0zPTJ{MEeyPS=>
FaDu MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWwOFjDqGh? NX:1cmNHUUN3ME22MlQ{yqEEsdMgNU4yO8LizszN Mk\QNlUzOjB5Mkm=
SCC25 M1nsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TYbVczyqCq NEi4ZZlKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= NXH3bXhvOjV{MkC3Nlk>
CAL27 M2nKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPDO|LDqGh? M1\j[2lEPTB;ND6yO:KhyrIEoEGuNVTDqM7:TR?= NEjjUZczPTJ{MEeyPS=>
FaDu NVjvOI5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLzOYVuPzMEoHi= NEnXbXBKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= NXfuOVJrOjV{MkC3Nlk>
MCF-7 M4THXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzHOWt2PDkEoHlCpC=> MVXEUXNQ MkDJTWM2OD15LkNCpOKyyqByLklCpO69VQ>? M4TVSFI2OjF4M{e4
T-47D NFvvdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHJ[VM1PDkEoHlCpC=> NIroWnhFVVOR NILwSo5KSzVyPUeuO:KhyrIEoECuO:Kh|ryP NF60dXozPTJzNkO3PC=>
MDA-MB-231 NHLx[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXEV5k1QMLiaNMg NYTvb3FbTE2VTx?= NVPER5N6UUN3ME2xNk45yqEEsdMgNU4xyqEQvF2= NETYTFAzPTJzNkO3PC=>
DU145 NYfrXmg4SXCxcITvd4l{KEG|c3H5 M372SVExNTFyMDFOwG0> MojTPEBp NGLxTJlFVVOR NXjZOVczcW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u MnjKNlUyPDl4OEG=
DU145 stem-like NV;PXYdXSXCxcITvd4l{KEG|c3H5 M1PvNlExNTFyMDFOwG0> NIfWUow5KGh? M3j2bmROW09? MnvCbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXeyOVE1QTZ6MR?=
DU145 Mly4SpVv[3Srb36gRZN{[Xl? NVHpb|Q2OTBvMUCwJO69VQ>? M{f4fVIhcA>? M17oXWROW09? NF3yb5lqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NILVbXQzPTF2OU[4NS=>
DU145 stem-like NEHyNpJHfW6ldHnvckBCe3OjeR?= M2HyZVExNTFyMDFOwG0> MWmyJIg> NFfMbJlFVVOR M1ewd4lv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnPMNlUyPDl4OEG=
UW228-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH4NE4xOS1|MECg{txO NHXmXGo1QCCq MWfEUXNQ M37XPWlEPTB;MD65PeKh|ryP MV2yOVEyQTF6NR?=
NSCs NH3FfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[wMlAyNTNyMDFOwG0> NID1dVA1QCCq NXf0cWQ4TE2VTx?= MoLoTWM2OD1yLkOtN:Kh|ryP NXWwdYJLOjVzMUmxPFU>
MKL-1  NV:4OYxTTnWwY4Tpc44hSXO|YYm= NX73dnRoOTBvMUCwNEBvVQ>? NHXacVA1KGR? MljNbY5lfWOnczD0bIUhcW6mdXP0bY9vKG:oIF3IR{1KKGW6cILld5Nqd25? NX;xXXRJOjVzMU[3OVQ>
MCF7 EV MVvGeY5kfGmxbjDBd5NigQ>? MUexNE0yODBizszN MonZNwKBkWh? NFnae2RqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? NUm2cHZWOjVyOEiyNFM>
MCF 7BMI1 NGTwZlRHfW6ldHnvckBCe3OjeR?= NGLxZWMyOC1zMECg{txO NWTEWXk3OuLCiXi= MoDCbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> NWjMSZJwOjVyOEiyNFM>
MCF7 EV NGHxXVRHfW6ldHnvckBCe3OjeR?= MXSxNE0yODBizszN NWTpVWdVOuLCiXi= NGXOeplGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> Ml7KNlUxQDh{MEO=
MCF7 BMI1 M{\xSWZ2dmO2aX;uJGF{e2G7 M{LpeFExNTFyMDFOwG0> MXSy5qCKcA>? MXfFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= NFHYWWUzPTB6OEKwNy=>
HepG2 NHzUToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHFZYhFVVORwrC= MnLzTWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= MlTGNlUxPzh|MUG=
MOLT-3 MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\EUXNQyqB? NUCyXIxtUUN3ME2wMlA2OcLiwsJCpFAvODB{wrFOwG0> NUfUO|BCOjVyN{izNVE>
HT1080 NVHRenlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH1VYgyNTFyMDFOwG0> M4rDUFQwOjRxNEigbC=> NGCxXXRFVVORwrC= NUH5U|F4cW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u M1\POVI2ODd6ME[0
HT1080 NWXSZYVCTnWwY4Tpc44hSXO|YYm= NHLYSpkxNjByMEGtNVAxKM7:TR?= MV2xMVI1KGh? Ml\oSG1UV8Li MmfQbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ NXjQ[mtHOjVyN{iwOlQ>
HT1080 M1HKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml20NE4xODBzLUGwNEDPxE1? MmrSNlQhcA>? MofQSG1UV8Li MVPjZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| M{TTcFI2ODd6ME[0
HD-MY-Z MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfqeY8zPC92OD:3NkBp M4L5c2lEPTExvK6xNFAh|ryP MoDKNlUxPDh{M{[=
DOHH-2 M3fqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjwNlQhcA>? NXfPdZFtUUN3MP-8olExOCEQvF2= MlLoNlUxPDh{M{[=
DOHH-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nyR|Q5KGh? MlvDTWM2OD1zOT65xsDPxE1? MXiyOVA1QDJ|Nh?=
DOHH-2 NXi1eVUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm3NkBp M1fQTWlEPTB;NdMg{txO NWLwWnlFOjVyNEiyN|Y>
REH Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTvZ5RqOjRiaB?= NUHSWHh5UUN3ME2wMlAzP8LizszN NV;6UZhsOjVyNEiyN|Y>
REH MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pn[FQ5KGh? M3SwNmlEPTB;MD6wNVTDqM7:TR?= MUmyOVA1QDJ|Nh?=
REH NEXzPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvrc4c2PzJiaB?= NYfWUHE6UUN3ME2wMlAyPcLizszN NVTI[4NPOjVyNEiyN|Y>
HH NWm3VYI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTFNlQhcA>? NVLLb3hzUUN3ME2xNFQvP8LizszN NH74SpYzPTB2OEKzOi=>
HH M3v2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF73eoc1QCCq MnHwTWM2OD12OD62xsDPxE1? NHTxXnMzPTB2OEKzOi=>
HH Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofXO|IhcA>? M4\zTGlEPTB;MUSuO:Kh|ryP MWSyOVA1QDJ|Nh?=
HuT-78 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnLNlQhcA>? M4rnOGlEPTB;OT6zxsDPxE1? NHPYXXMzPTB2OEKzOi=>
HuT-78 M2X3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi4[pY1QCCq MnvVTWM2OD12LkRCpO69VQ>? NVu1Umw5OjVyNEiyN|Y>
HuT-78 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHWO|IhcA>? MmPxTWM2OD12LkNCpO69VQ>? MWCyOVA1QDJ|Nh?=
OPM-2 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmyOEBp MmThTWM2OD1{ND6xxsDPxE1? NXTzOnRqOjVyNEiyN|Y>
OPM-2 NXPzVHNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkiyOFghcA>? M2DkZWlEPTB;NNMg{txO MmT2NlUxPDh{M{[=
OPM-2 M12wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnvO|IhcA>? MmnmTWM2OD1zLkRCpO69VQ>? MnzDNlUxPDh{M{[=
RPMI-8226 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHsNlQhcA>? NIfCcpVKSzVyPUGwOk43yqEQvF2= MlzZNlUxPDh{M{[=
RPMI-8226 Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTGOFghcA>? MlrmTWM2OD17MT6xxsDPxE1? Mk\WNlUxPDh{M{[=
RPMI-8226 NWPJZZB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLWO|IhcA>? MnmwTWM2OD1zND65xsDPxE1? M33hR|I2ODR6MkO2
U-266 M1TwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWiyOEBp NYrYT3c3UUN3ME24Ok4zyqEQvF2= M2TZ[|I2ODR6MkO2
U-266 M1rtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjEd5V{PDhiaB?= NETIcm1KSzVyPU[4MlTDqM7:TR?= M3zLTlI2ODR6MkO2
U-266 NUHHVGtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYm3NkBp MkG3TWM2OD1{Nz60xsDPxE1? MlXnNlUxPDh{M{[=
Kelly MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfvdGxxOC1zMDFOwG0> NHrsZWc4OsLiaB?= NFjEfFdKSzVyPUGuOVE5yqEQvF2= M2Wxc|I2ODB6OUCw
SH-SY5Y  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XRXVAuOTBizszN NHPndFQ4OsLiaB?= NV[zToRXUUN3ME2wMlc2PMLizszNxsA> MUCyOVAxQDlyMB?=
SK-N-AS NVG0bZhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDMNGxHOC1zMDFOwG0> MU[3NuKhcA>? M3z2XGlEPTB;MT63NVLDqM7:TdMg MXqyOVAxQDlyMB?=
SK-N-DZ MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1npVFAuOTBizszN MYS3NuKhcA>? Moj1TWM2OD13LkS4OeKh|ryP M4[0R|I2ODB6OUCw
HepG2 M3G4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDBOFjDqGh? MWLEUXNQyqB? M1HQS2lEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= NXixW4xJOjR7OU[xN|Y>
A549 NWTQTGtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PC[FQ5yqCq MWrEUXNQyqB? MVfJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NYmycmV4OjR7OU[xN|Y>
MCF7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjRfItKPDkEoHi= MnzHSG1UV8Li NV3mdmhHUUN3ME24NU4xQcLiwsJCpFE1NjJzwrFOwG0> MXyyOFk6PjF|Nh?=
HL-60  MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn0cmk2PzMEoHi= NH;nUVBKSzVyPUCuNVLjiIYQvF2= NXfEXFNUOjR7OUOwNVQ>
HL-60[R] MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTVO|LDqGh? MkLsTWM2OD1|LkGy5qCG|ryP NYP4SGUzOjR7OUOwNVQ>
MIAPACA NGnsWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDFWnN{T0l3ME2xMlMhyrFiMD6wN{DPxE1? MmntNlQ6PTN6MkG=
MCF-7 M{LTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrGcFJIUTVyPUCuNlUhyrFiMD6xJO69VQ>? M4eyb|I1QTV|OEKx
HeLa M4nBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvZS2k2OD1yLk[0JOKyKDBwNDFOwG0> MYWyOFk2Ozh{MR?=
MO59K  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fwOFch\A>? NIL3WXpKSzVyPUCuNVfjiIYQvF2= M1O0VFI1QTV|NU[x
MO59J M2LZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO3JIQ> MmLNTWM2OD1yLkJihKXPxE1? M1LrXFI1QTV|NU[x
ME 180 NFTZVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LGSlQ5yqCqwrC= MXjJR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? M2joZlI1QTV|MEK3
MCF-7 M{DkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe0POKhcMLi MWHJR|UxRTJ|LkmgxtEhOC5|4pEF{txO NHTFdWkzPDl3M{CyOy=>
HeLa NE\SOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDlPGJiPDkEoHlCpC=> MoHkTWM2OD12LkexJOKyKDFwNPMAie69VQ>? Mm[2NlQ6PTNyMke=
MDA-MB-453 NIPqZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfTflk1QMLiaNMg NF;ubYNKSzVyPUGyMlUhyrFiMD64OgKBjc7:TR?= M3LIclI1QTV|MEK3
MDA-MB-231 NVTFfYtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KyflQ5yqCqwrC= MWjJR|UxRTJ2LkKyJOKyKDJwOUVihKXPxE1? NYmwdHhxOjR7NUOwNlc>
PC-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHSOFjDqGkEoB?= NWXnbWNbUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= MmHhNlQ6PTNyMke=
HT-29 M3ftSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlewOFjDqGkEoB?= NHTjdXRKSzVyPUKxMlQ2KMLzIEOuPFfjiIYQvF2= M{TzU|I1QTV|MEK3
BGC-823 MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XRO|Q5yqCqwrC= M{XFOGlEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= NIrSXHozPDd7M{i3Oy=>
HeLa MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\sXnI1QMLiaNMg NVHSenBQUUN3ME2yNFkvQTBiwsGgNVMvPDJi4pEF{txO M3\LNFI1Pzl|OEe3
A549 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LHO|Q5yqCqwrC= MXnJR|UxRTF|OT61OEDDuSB5LkC15qCG|ryP MoLiNlQ4QTN6N{e=
HK-2 NEXIRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEflWlQ1QMLiaNMg M{jlbmlEPTB;OT6xO{DDuSBzLkW45qCG|ryP M3;uOFI1Pzl|OEe3

... Click to View More Cell Line Experimental Data

体内研究 Etoposide 作用于Lewis 肺癌,诱导肿瘤免疫。Etoposide按50 mg/kg剂量单独腹腔注射给药注射了Lewis肺癌细胞 (3LL)的C57B1/6小鼠,诱导60%存活。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[5]
+ 展开

Topoisomerase II 活性测定:

制备核提取物,进行核分离。在Topoisomerase II去连环过程中获得去连环百分数而计算Topoisomerase II的活性。氚标记的kinoplast DNA (KDNA 0.22 μg)作为底物。Etoposide 与 Topoisomerase II在37°C 下温育30分钟,然后加入1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止。通过Etoposide获得去连环百分数和 Topoisomerase II 抑制情况。
细胞实验:[5]
+ 展开
  • Cell lines: 人类胶质瘤细胞系CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 小时
  • Method: Etoposide处理后,使用含有0.03%胰蛋白酶和0.27 mM乙二胺四乙酸(EDTA)的磷酸盐缓冲液(PBS)将细胞从培养皿中移去,然后在培养皿中稀释到适当数目,获得20到200个菌落。12天后,使用甲醇-乙酸固定培养基,使用结晶紫进行染色,并计数超过50个细胞的菌落。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带血管肉瘤移植瘤ISOS-1 的小鼠
  • Formulation: 生理盐水
  • Dosages: 10 mg/kg
  • Administration: 从实验第7天开始,每天腹腔注射,持续5天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
5% DMSO+30% PEG 300+H2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 588.56
化学式

C29H32O13

CAS号 33419-42-0
稳定性 powder
别名 VP-16, VP-16213

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Etoposide | Etoposide供应商 | 采购Etoposide | Etoposide价格 | Etoposide生产 | 订购Etoposide | Etoposide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID